NOISESaved copy
Coverage history

Assembled by NOISE.

Saved report copy

Recorded

FDA proposes easier access to unproven peptide drugs

The FDA has submitted an "Interim Access Policy" on peptide drugs for White House review under Health Secretary Robert F. Kennedy Jr. According to the Associated Press, the policy would grant "enforcement discretion," allowing the agency to decline enforcement of restrictions on certain peptides and reassure specialty pharmacies making them. In 2023, FDA scientists found the peptides lack safety and efficacy data and pose risks, and removed them from the compounding list; the agency is now re-reviewing 12 of the drugs after a panel weighted with new members tied to peptide businesses recommended restoring six. Advocacy group CSPI has urged acting FDA Commissioner Kyle Diamantas to disregard the recommendations, warning consumers face risk of serious injury from unsupported claims, while formal rulemaking to restore the peptides could take years, making enforcement discretion a faster path to access.